Literature DB >> 15220431

Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching.

Cristina Pastore1, Alejandra Ramos, Donald E Mosier.   

Abstract

The natural evolution of human immunodeficiency virus type 1 infection often includes a switch in coreceptor preference late in infection from CCR5 to CXCR4, a change associated with expanded target cell range and worsened clinical prognosis. Why coreceptor switching takes so long is puzzling, since it requires as few as one to two mutations. Here we report three obstacles that impede the CCR5-to-CXCR4 switch. Coreceptor switch variants were selected by target cell replacement in vitro. Most switch variants showed diminished replication compared to their parental R5 isolate. Transitional intermediates were more sensitive to both CCR5 and CXCR4 inhibitors than either the parental R5 virus or the final R5X4 (or rare X4) variant. The small number of mutations in viruses selected for CXCR4 use were distinctly nonrandom, with a dominance of charged amino acid substitutions encoded by G-to-A transitions, changes in N-linked glycosylation sites, and isolate-specific mutation patterns. Diminished replication fitness, less-efficient coreceptor use, and unique mutational pathways may explain the long delay from primary infection until the emergence of CXCR4-using viruses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15220431      PMCID: PMC434079          DOI: 10.1128/JVI.78.14.7565-7574.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1.

Authors:  G Alkhatib; C Combadiere; C C Broder; Y Feng; P E Kennedy; P M Murphy; E A Berger
Journal:  Science       Date:  1996-06-28       Impact factor: 47.728

2.  Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.

Authors:  A Trkola; T J Ketas; K A Nagashima; L Zhao; T Cilliers; L Morris; J P Moore; P J Maddon; W C Olson
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

3.  N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism.

Authors:  R A Ogert; M K Lee; W Ross; A Buckler-White; M A Martin; M W Cho
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

4.  Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells.

Authors:  M Janini; M Rogers; D R Birx; F E McCutchan
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

5.  Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks.

Authors:  W Resch; N Hoffman; R Swanstrom
Journal:  Virology       Date:  2001-09-15       Impact factor: 3.616

6.  T-cell line adaptation of human immunodeficiency virus type 1 strain SF162: effects on envelope, vpu and macrophage-tropism.

Authors:  Nathalie Dejucq; Graham Simmons; Paul R Clapham
Journal:  J Gen Virol       Date:  2000-12       Impact factor: 3.891

7.  Reduced fitness of HIV-1 resistant to CXCR4 antagonists.

Authors:  Mercedes Armand-Ugón; Miguel E Quiñones-Mateu; Arantxa Gutiérez; Jordi Barretina; Julià Blanco; Dominique Schols; Erik De Clercq; Bonaventura Clotet; José A Esté
Journal:  Antivir Ther       Date:  2003-02

8.  Differential coreceptor expression allows for independent evolution of non-syncytium-inducing and syncytium-inducing HIV-1.

Authors:  R P van Rij; H Blaak; J A Visser; M Brouwer; R Rientsma; S Broersen; A M de Roda Husman; H Schuitemaker
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

9.  Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES.

Authors:  Cristina Pastore; Gastón R Picchio; Francesco Galimi; Richard Fish; Oliver Hartley; Robin E Offord; Donald E Mosier
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

10.  Germinal center initiation, variable gene region hypermutation, and mutant B cell selection without detectable immune complexes on follicular dendritic cells.

Authors:  L G Hannum; A M Haberman; S M Anderson; M J Shlomchik
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

View more
  42 in total

1.  Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism.

Authors:  Jeannette M Whitcomb; Wei Huang; Signe Fransen; Kay Limoli; Jonathan Toma; Terri Wrin; Colombe Chappey; Linda D B Kiss; Ellen E Paxinos; Christos J Petropoulos
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

2.  Naïve and memory cell turnover as drivers of CCR5-to-CXCR4 tropism switch in human immunodeficiency virus type 1: implications for therapy.

Authors:  Ruy M Ribeiro; Mette D Hazenberg; Alan S Perelson; Miles P Davenport
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations.

Authors:  C Pastore; R Nedellec; A Ramos; S Pontow; L Ratner; D E Mosier
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

4.  Evolution of CXCR4-using human immunodeficiency virus type 1 SF162 is associated with two unique envelope mutations.

Authors:  Yana Kiselyeva; Rebecca Nedellec; Alejandra Ramos; Cristina Pastore; Leonid B Margolis; Donald E Mosier
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

5.  Conserved changes in envelope function during human immunodeficiency virus type 1 coreceptor switching.

Authors:  Cristina Pastore; Rebecca Nedellec; Alejandra Ramos; Oliver Hartley; John L Miamidian; Jacqueline D Reeves; Donald E Mosier
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

Review 6.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

7.  Female genital tract shedding of CXCR4-tropic HIV Type 1 is associated with a majority population of CXCR4-tropic HIV Type 1 in blood and declining CD4(+) cell counts.

Authors:  Richard E Haaland; Sharon T Sullivan; Tammy Evans-Strickfaden; Jeffrey L Lennox; Clyde E Hart
Journal:  AIDS Res Hum Retroviruses       Date:  2012-03-23       Impact factor: 2.205

8.  HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120.

Authors:  Annette N Ratcliff; Wuxian Shi; Eric J Arts
Journal:  J Virol       Date:  2012-11-07       Impact factor: 5.103

9.  Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient.

Authors:  Evelien M Bunnik; Esther D Quakkelaar; Ad C van Nuenen; Brigitte Boeser-Nunnink; Hanneke Schuitemaker
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

10.  Evolution of CCR5 use before and during coreceptor switching.

Authors:  Mia Coetzer; Rebecca Nedellec; Janelle Salkowitz; Sherry McLaughlin; Yi Liu; Laura Heath; James I Mullins; Donald E Mosier
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.